Form 4: ATAI Life Sciences Executive Acquires Stock Options and Settles Restricted Stock Units
SEC Form 4 Filing
Sahil Kirpekar, Chief Business Officer of ATAI Life Sciences N.V., reports acquisition of stock options and settlement of restricted stock units.
Summary
- Sahil Kirpekar, Chief Business Officer of ATAI Life Sciences N.V., filed a Form 4 detailing changes in beneficial ownership.
- On March 14, 2024, Kirpekar settled 100,000 restricted stock units (RSUs), receiving 100,000 common shares.
- On March 13, 2024, Kirpekar acquired 550,000 stock options with an exercise price of $1.84.
- The stock options vest 25% on January 1, 2025, and the remainder in 36 equal monthly installments thereafter.
- The RSUs vest 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of executive compensation. The vesting schedule and exercise price are typical components of such agreements.
Industry Context
Form 4 filings are standard practice and provide transparency into executive compensation and ownership changes, which are closely monitored by investors.
Stakeholder Impact
- Shareholders may view this as a standard part of executive compensation.
- Employees may see this as an incentive for management.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of stock option grant (550,000 options at $1.84 exercise price). |
| 03/14/2024 | Date of restricted stock unit settlement (100,000 shares). |
| 03/15/2024 | Date of Form 4 filing. |
| 01/01/2025 | First vesting date for 25% of the stock options. |
| 03/13/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.